Method For Using Composition With Enhanced Passenger Molecule Loading
A composition comprising surfactant-enhanced phospholipid vesicles with one or more cannabinoid substance encapsulated therein is disclosed, wherein one or more surfactant is utilized for enhancing loading and increasing encapsulation efficiency of cannabinoid passenger molecules within phospholipid structures. A method is disclosed for making a surfactant-enhanced phospholipid vesicles with one or more cannabinoid substance encapsulated therein, wherein one or more surfactant is used for enhancing loading and increasing encapsulation efficiency of passenger molecules in phospholipid structures. A method of using surfactant-enhanced phospholipid vesicles with one or more cannabinoid substance encapsulated therein is disclosed wherein one or more surfactant enhances loading and increases encapsulation efficiency of cannabinoid substances in phospholipid structures. A composition and method of making surfactant-enhanced phospholipid vesicles with one or more lipophilic passenger substance encapsulated therein is disclosed wherein one or more surfactant is utilized for enhancing loading and increasing encapsulation efficiency of passenger molecules within phospholipid structures.
1 . A method for administering a cannabinoid substance in an oral delivery protocol comprising the steps of:
providing a cannabinoid encapsulate having one or more cannabinoid substance encapsulated in one or more surfactant-enhanced phospholipid vesicles having phospholipids, ethanol, water, and one or more surfactant selected from Polysorbates and derivatives, PEG esters of hydrogenated castor oil and derivatives, and combinations thereof, wherein said cannabinoid substance in said cannabinoid encapsulate has a concentration of 3 mg/mL to 300 mg/mL, and said cannabinoid encapsulate has less than 2% water (w/w) and up to 25% (w/w) of said surfactant; and
administering a quantity of the cannabinoid encapsulate having 1 mg to 100 mg of the cannabinoid substance orally to a subject.
2 . The method of claim 1 , wherein the cannabinoid substance is selected from cannabidiol (CBD), tetrahydrocannabinol (THC), a whole plant extract of Cannabis sativa , a whole plant extract of Cannabis indica and combinations thereof.
3 . The method of claim 2 , wherein the cannabinoid substance is cannabidiol (CBD), tetrahydrocannabinol (THC), or a combination of cannabidiol (CBD) and tetrahydrocannabinol (THC).
4 . The method of claim 1 , wherein the surfactant is Polysorbate (Tween) 80, PEG-40 hydrogenated castor oil, or combinations thereof.
5 . The method of claim 1 , wherein the cannabinoid encapsulate is delivered orally as a beverage having from 1.5 ounce to 12 ounces.
6 . The method of claim 1 , wherein the cannabinoid encapsulate is delivered orally as a shot having 1.5 ounce or less.
7 . The method of claim 1 , wherein the cannabinoid encapsulate is delivered orally as a swish and swallow preparation having 1.0 ounce or less.
8 . The method of claim 7 , wherein the swish and swallow preparation remains in contact with the subject's oral cavity for 30 seconds to 5 minutes.
9 . The method of claim 1 , further comprising combining said cannabinoid encapsulate with one or more excipient ingredients suitable for an oral preparation delivered via said beverage, shot, or swish and swallow oral preparation, said excipient ingredients being for stabilization, appearance, flavoring, or dilution of the oral preparation.
10 . The method of claim 1 , further comprising combining said cannabinoid encapsulate with one or more sweeteners, flavorings, vitamins, minerals, herbs or herbal extracts, fruit extracts, vegetable extracts, spices or spice extracts, caffeine, amino acids, or nutraceutical ingredients suitable for delivery in an oral preparation.
11 . The method of claim 1 , wherein said cannabinoid substance further comprises Cannabis -derived terpenes, Cannabis -derived flavonoids, or combinations thereof.
12 . The method of claim 1 , wherein said cannabinoid substance is a Cannabis sativa -derived cannabinoid, Cannabis indica-derived cannabinoid, a synthetically derived cannabinoid, or combinations thereof.
13 . A method for intraoral transmucosal administration of a cannabinoid substance comprising the steps of:
providing a cannabinoid encapsulate having one or more cannabinoid substance encapsulated in one or more surfactant-enhanced phospholipid vesicle having phospholipids, ethanol, water, and one or more surfactant, wherein the cannabinoid encapsulate has less than 2% water (w/w), up to 25% (w/w) surfactant, and said cannabinoid substance in said cannabinoid encapsulate has a concentration of 3 mg/mL to 300 mg/mL;
administering a quantity of the cannabinoid encapsulate having 1 mg to 100 mg of said cannabinoid substance to a subject's oral mucosa, and
allowing the cannabinoid encapsulate to remain in contact with the oral mucosa for a period of time ranging from 1 minute to 10 minutes.
14 . The method of claim 13 , wherein the surfactant is Polysorbate (Tween) 80, PEG-40 hydrogenated castor oil, or combinations thereof.
15 . The method of claim 13 , wherein the cannabinoid encapsulate is kept in contact with the oral mucosa for 1 minute to 5 minutes.
16 . The method of claim 13 , further comprising combining said cannabinoid encapsulate with one or more excipient ingredients suitable for preparation of a liquid drop, liquid spray, aerosol, liquid shot, gel, paste, lozenge, gum, gummy candy, hard candy, orally dissolving strip, tablet, or swish and swallow preparation for transmucosal delivery, said excipient ingredients are for stabilization, appearance, flavoring, dilution, or adherence of the transmucosal preparation.
17 . The method of claim 13 , wherein the cannabinoid encapsulate is applied to the oral mucosa as a liquid drop, liquid spray, aerosol, liquid shot, gel, paste, lozenge, gum, gummy candy, hard candy, orally dissolving strip, tablet, or swish and swallow preparation.
18 . The method of claim 13 , further comprising combining said cannabinoid encapsulate with one or more sweeteners, flavorings, vitamins, minerals, herbal ingredients and extracts, fruit extracts, vegetable extracts, spices or spice extracts, caffeine, amino acids, and nutraceutical ingredients suitable for delivery via a transmucosal preparation.
19 . The method of claim 13 , wherein said cannabinoid substance is a Cannabis sativa -derived cannabinoid, Cannabis indica-derived cannabinoid, a synthetically derived cannabinoid, or combinations thereof
20 . A method for administration of a cannabinoid substance to an epidermal area comprising the steps of:
providing a cannabinoid encapsulate having one or more cannabinoid substance encapsulated in one or more surfactant-enhanced phospholipid vesicles having phospholipids, ethanol, water, and one or more surfactant, wherein the cannabinoid encapsulate has less than 2% water (w/w), up to 25% (w/w) surfactant, and said cannabinoid substance in said cannabinoid encapsulate has a concentration of 3 mg/mL to 300 mg/mL;
administering a quantity of the cannabinoid encapsulate having 1 mg to 100 mg of cannabinoid substance topically to the epidermal area, and
allowing the cannabinoid encapsulate to remain in contact the epidermal area for a period of time ranging from 1 minute to 24 hours.
21 . The method of claim 20 , wherein the cannabinoid substance is selected from cannabidiol (CBD), tetrahydrocannabinol (THC), Cannabis -derived terpenes, Cannabis -derived flavonoids, a whole plant extract of Cannabis sativa , a whole plant extract of Cannabis indica and combinations thereof.
22 . The method of claim 21 , wherein the cannabinoid substance is cannabidiol (CBD), tetrahydrocannabinol (THC), or a combination of cannabidiol (CBD) and tetrahydrocannabinol (THC).
23 . The method of claim 20 , wherein the surfactant is polysorbate (Tween) 80, PEG-40 hydrogenated castor oil, or combinations thereof.
24 . The method of claim 20 , further comprising combining the cannabinoid encapsulate with one or more excipient ingredient suitable for a topical or transdermal preparation of a cream, lotion, ointment, wax, topically applied spray, gel, balm or transdermal patch for topical or transdermal administration of the cannabinoid encapsulate, said excipient ingredients are for stabilization, appearance, dilution, or adherence of said topical or transdermal preparation.
25 . The method of claim 20 , wherein the cannabinoid encapsulate is applied to the epidermis in a cream, lotion, ointment, wax, topically applied spray, gel, or balm.
26 . The method of claim 20 , wherein the cannabinoid encapsulate is applied to the epidermis in a transdermal patch.
27 . The method of claim 20 , wherein said cannabinoid substance is a Cannabis sativa -derived cannabinoid, Cannabis indica-derived cannabinoid, a synthetically derived cannabinoid, or combinations thereof.